Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study

被引：0

作者：

Facon, Thierry ^{[1
]}

Moreau, Philippe ^{[2
]}

Spicka, Ivan ^{[3
]}

Suzuki, Kenshi ^{[4
]}

Yong, Kwee ^{[5
]}

Mikhael, Joseph ^{[6
]}

Fukao, Taro ^{[7
]}

Bisht, Kamlesh ^{[7
]}

Armstrong, Nicole ^{[8
]}

Mace, Sandrine ^{[9
]}

Risse, Marie-Laure ^{[10
]}

Martin, Thomas ^{[11
]}

机构：

[1] Lille Univ Hosp, Dept Hematol, Lille, France

[2] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[3] Charles Univ & Gen Hosp, Fac Med 1, Dept Hematol, Prague, Czech Republic

[4] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan

[5] Univ Coll Hosp, Dept Haematol, London, England

[6] City Hope Canc Ctr, Translat Genom Res Inst, Phoenix, AZ USA

[7] Sanofi, Global Oncol, Cambridge, MA USA

[8] Sanofi, Global Med Affairs, Cambridge, MA USA

[9] Sanofi, Res & Dev, Chilly Mazarin, France

[10] Sanofi, Res & Dev, Vitry Sur Seine, France

[11] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

1q21; IKEMA; isatuximab; carfilzomib; dexamethasone; multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-248

引用

页码：S484 / S485

页数：2

共 50 条

[21] Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)
Berenson, James
Cartmell, Alan
Lyons, Roger
Harb, Wael
Tzachanis, Dimitrios
Agajanian, Richy
Boccia, Ralph V.
Coleman, Morton
Moss, Robert A.
Rifkin, Robert M.
Schupp, Marco
Dixon, Sandra
Ou, Ying
Anderl, Janet
Berdeja, Jesus G.
BLOOD, 2015, 126 (23)
[22] WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)
Berenson, J.
Cartmell, A.
Lyons, R. M.
Harb, W.
Tzachanis, D.
Boccia, R.
Rifkin, R. M.
Patel, P.
Dixon, S.
Berdeja, J.
HAEMATOLOGICA, 2015, 100 : 81 - 81
[23] WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)
Berenson, J.
Cartmell, A.
Lyons, R.
Harb, W.
Tzachanis, D.
Agajanian, R.
Boccia, R.
Coleman, M.
Moss, R. A.
Rifkin, R. M.
Schupp, M.
Dixon, S.
Ou, Y.
Anderl, J.
Berdeja, J.
HAEMATOLOGICA, 2016, 101 : 261 - 262
[24] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Stewart, A. Keith
Rajkumar, S. Vincent
Dimopoulos, Meletios A.
Masszi, Tamas
Spicka, Ivan
Oriol, Albert
Hajek, Roman
Rosinol, Laura
Siegel, David S.
Mihaylov, Georgi G.
Goranova-Marinova, Veselina
Rajnics, Peter
Suvorov, Aleksandr
Niesvizky, Ruben
Jakubowiak, Andrzej
San Miguel, Jesus F.
Ludwig, Heinz
Zojwalla, Naseem
Tonda, Margaret E.
Xing, Biao
Moreau, Philippe
Palumbo, Antonio
BLOOD, 2014, 124 (21)
[25] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos, Meletios
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10245): : 186 - 197
[26] EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDY
Dimopoulos, M. A.
Stewart, A. K.
Rajkumar, S. V.
Masszi, T.
Spicka, I.
Oriol, A.
Hajek, R.
Rosinol, L.
Siegel, D.
Mihaylov, G. G.
Goranova-Marinova, V.
Rajnics, P.
Suvorov, A.
Niesvizky, R.
Jakubowiak, A.
San-Miguel, J.
Ludwig, H.
Zojwalla, N.
Tonda, M.
Yang, X.
Moreau, P.
Palumbo, A.
HAEMATOLOGICA, 2015, 100 : 151 - 152
[27] Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Siegel, David S.
Oriol, Albert
Rajnics, Peter
Minarik, Jiri
Hungria, Vania
Lee, Jae Hoon
Song, Kevin
Obreja, Mihaela
Aggarwal, Sanjay
Hajek, Roman
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E142 - E142
[28] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
[29] Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus F.
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Sy.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
Van de Velde, Helgi
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Kouri, Fotini
Liboon, John
Brawley, Chris
Lewis, Eric
Tubel, Gabriela
Li, Mary
McKeown, Astrid
Roy-Ghanta, Sumita
Opalinska, Joanna
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262

← 1 2 3 4 5 →